Cboe UK GBp

AstraZeneca PLC (AZNL.XC)

10,214.00

+28.00

+(0.27%)

At close: May 9 at 4:29:55 PM GMT+1

AstraZeneca (LSE:AZN) Reports Positive Results From Phase III IMFINZI Trial In Bladder Cancer

AstraZeneca (LSE:AZN) recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting significant advancements in treatment for high-risk non-muscle-invasive bladder cancer. This development coincided with a 5.93% share price increase over the past month. The company's recent announcements, such as the Calquence approval in the EU and positive results from the DESTINY-Breast11 trial, have reinforced its commitment to innovative treatments. While market...

Simply Wall St. yesterday

AZN

AZNCF
How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%

The consensus price target hints at a 27.9% upside potential for Astrazeneca (AZN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 2 days ago

AZN
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update

NVO and JAZZ report first-quarter results. AZN's asthma study on Breztri meets key goals.

Zacks 2 days ago

NVO

AZN

JAZZ
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

WILMINGTON, Del., May 09, 2025--Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca’s IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance therapy alone.

Business Wire 2 days ago

AZN

AZNCF
AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial

The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, and invasive disease-free survival.

Clinical Trials Arena 3 days ago

AZN

4568.T
AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment

AstraZeneca (LSE:AZN) recently experienced positive developments, including the European approval of Calquence for mantle cell lymphoma and promising Phase III trial results for ENHERTU in breast cancer. These advances in oncology could add depth to the company's market performance. Meanwhile, broader market trends showed mixed movements, with the Dow Jones and S&P 500 rising, while Nasdaq slipped slightly. Despite a flat market overall last week due to investor anticipation of the Federal...

Simply Wall St. 4 days ago

AZN

AZNCF
Q1 2025 Arcus Biosciences Inc Earnings Call

Q1 2025 Arcus Biosciences Inc Earnings Call

Thomson Reuters StreetEvents 4 days ago

RCUS

AZN
Expediting parallel drug approval pathways is challenging, but rewarding

A panel at Swiss Biotech Day 2025 discussed three global parallel drug approval pathways.

Pharmaceutical Technology 4 days ago

AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

WILMINGTON, Del., May 07, 2025--Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with h

Business Wire 4 days ago

AZN

AZNCF
EC approves AstraZeneca’s Calquence combo to treat MCL

The EC’s decision was supported by outcomes from the ECHO Phase III trial.

Pharmaceutical Technology 4 days ago

AZN
Tempus AI Inc (TEM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...

Tempus AI Inc (TEM) reports a 75.4% revenue increase and a significant $200 million partnership, setting the stage for a promising fiscal year.

GuruFocus.com 4 days ago

TEM

AZN
AstraZeneca unveils new factory as part of multibillion-dollar investment in US manufacturing

AstraZeneca has opened its first U.S.-operated cell therapy manufacturing plant in Rockville, Maryland, as part of its ongoing $3.5 billion investment in American innovation.

Fox Business 5 days ago

AZN
AZN or ARGX: Which Is the Better Value Stock Right Now?

AZN vs. ARGX: Which Stock Is the Better Value Option?

Zacks 5 days ago

AZN
AstraZeneca's (LON:AZN) Earnings Offer More Than Meets The Eye

The market seemed underwhelmed by last week's earnings announcement from AstraZeneca PLC ( LON:AZN ) despite the...

Simply Wall St. 5 days ago

AZN

AZNCF
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 6 days ago

AZN
AstraZeneca First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

AstraZeneca ( LON:AZN ) First Quarter 2025 Results Key Financial Results Revenue: US$13.6b (up 7.2% from 1Q 2024). Net...

Simply Wall St. 7 days ago

AZN

AZNCF
AstraZeneca (LSE:AZN) Announces Positive Results From Breztri Trials For Uncontrolled Asthma

AstraZeneca (LSE:AZN) recently announced phase III trial results for Breztri Aerosphere, its triple-combination asthma therapy, marking a milestone in improving care standards for asthma patients. This announcement comes amidst the company's robust Q1 2025 financial performance, which showed significant gains in sales, revenue, and net income. Meanwhile, the broader market rose by 1.8% last week, buoyed by positive macroeconomic indicators such as strong jobs data. AstraZeneca's share price...

Simply Wall St. 9 days ago

AZN

AZNCF
Here's what top C-suites are saying about tariffs

US President Trump's tariff policies have created a challenging environment for business leaders. Here's what some executives are saying about navigating tariffs, including CEOs from Coca-Cola (KO), Starbucks (SBUX), and AstraZeneca (AZN), and top executives at Meta (META), General Motors (GM), and Amazon (AMZN). To watch more expert insights and analysis on the latest market action, check out more Wealth here.

Yahoo Finance Video 9 days ago

AAPL

KO

AMZN
European Equities Close Sharply Higher in Friday Trading; Eurozone Inflation Unchanged at 2.2%

The European stock markets closed sharply higher in Friday trading as the Stoxx Europe 600 climbed 1

PREMIUM
MT Newswires 9 days ago

^GDAXI

^FTSE

^FCHI
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma

On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials assessed the efficacy and safety of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) compared with two fixed-dose, dual-combination therapies of budesonid (an ICS) and formoterol fumarate (LABA) and Symbicort pressurized metered-dose inhaler (pMDI). KALOS and LOGOS included approximately 4,400 randomized patients.

Benzinga 9 days ago

AZN

Performance Overview

Return	AZNL.XC	FTSE 100 (^FTSE)
YTD	-2.28%	+4.67%
1-Year	-17.24%	+2.07%
3-Year	+0.67%	+18.54%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AstraZeneca PLC (AZNL.XC)

AstraZeneca (LSE:AZN) Reports Positive Results From Phase III IMFINZI Trial In Bladder Cancer

How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%

Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial

AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment

Q1 2025 Arcus Biosciences Inc Earnings Call

Expediting parallel drug approval pathways is challenging, but rewarding

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

EC approves AstraZeneca’s Calquence combo to treat MCL

Tempus AI Inc (TEM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...

AstraZeneca unveils new factory as part of multibillion-dollar investment in US manufacturing

AZN or ARGX: Which Is the Better Value Stock Right Now?

AstraZeneca's (LON:AZN) Earnings Offer More Than Meets The Eye

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

AstraZeneca First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

AstraZeneca (LSE:AZN) Announces Positive Results From Breztri Trials For Uncontrolled Asthma

Here's what top C-suites are saying about tariffs

European Equities Close Sharply Higher in Friday Trading; Eurozone Inflation Unchanged at 2.2%

AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma

Performance Overview